Brenda Armenti-Kapros, MD
Endocrinology · Mechanicsville, VANPI 1689642464
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,242 of the $76,882 with a category attached, or 75.8%. 40 manufacturers reported payments, led by Novo Nordisk at 57.0% of the total. Reporting peaked in 2019 at $25,767 and has fallen 95.9% since, to $1,056 in 2025.
Across 613 payments — averaging $125.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$44K
- AstraZeneca$14K
- Merck$5K
- Zealand Pharma US, Inc.$4K
- Intuity Medical Inc$3K
- Lilly USA, LLC$1K
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$58,24276%
- Travel & lodging$4,6626%
- Food & beverage$13,85318%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 110 | $43,847 |
| AstraZeneca | 125 | $13,692 |
| Merck | 22 | $5,211 |
| Zealand Pharma US, Inc. | 39 | $3,990 |
| Intuity Medical Inc | 1 | $2,800 |
| Lilly USA, LLC | 58 | $1,203 |
| Valeritas, Inc. | 34 | $803 |
| Abbott | 36 | $679 |
| Amgen | 21 | $595 |
| Bayer | 9 | $358 |
| Sanofi-aventis U.S. LLC | 15 | $340 |
| Mannkind Corporation | 16 | $329 |
| AbbVie | 16 | $312 |
| Dexcom, Inc. | 8 | $255 |
| Medtronic(2 entities) | 15 | $254 |
| Insulet Corporation | 5 | $242 |
| Radius Health, Inc. | 7 | $187 |
| Xeris Pharmaceuticals, Inc. | 6 | $183 |
| Cequr Corporation | 2 | $179 |
| Amneal Pharmaceuticals LLC | 11 | $177 |
| Antares Pharma, Inc. | 8 | $151 |
| Boehringer Ingelheim | 8 | $149 |
| Lifescan, Inc. | 5 | $117 |
| Tandem Diabetes Care, Inc. | 8 | $115 |
| Astellas Pharma US Inc | 3 | $113 |
| AMAG Pharmaceuticals, Inc. | 1 | $99 |
| Clarus Therapeutics Inc. | 1 | $83 |
| Tolmar, Inc. | 4 | $65 |
| IBSA Pharma Inc. | 3 | $58 |
| Novartis | 2 | $46 |
| Eisai Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Pfizer | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$17,977
- RYBELSUS$16,348
- FARXIGA$11,579
- Tresiba$7,124
- STEGLATRO$4,954
- Pogo Automatic Blood Glucose Monitoring System$2,800
- V-GO DISPOSABLE INSULIN DELIVERY$1,912
- V-GO$1,667
- CeQur Simplicity$161
- MOUNJARO$125
- Wegovy$124
- DEXCOM G6 TRANSMITTER$117
- EVENITY$115
- FREESTYLE LIBRE 3$111
- Repatha$111
- Kerendia$108
- AFREZZA$105
- TRULICITY$100
How this compares
Too few endocrinology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $338,237 |
| MounjaroTirzepatide | 193 | $219,005 |
| TrulicityDulaglutide | 124 | $186,965 |
| Xigduo XrDapaglifloz Propaned/Metformin | 107 | $131,672 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 114 | $118,975 |
| JardianceEmpagliflozin | 116 | $114,331 |
| FarxigaDapagliflozin Propanediol | 89 | $84,749 |
| RybelsusSemaglutide | 32 | $54,271 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $47,693 |
| SynjardyEmpagliflozin/Metformin Hcl | 79 | $46,731 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $33,364 |
| JanuviaSitagliptin Phosphate | 24 | $33,041 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $20,906 |
| SynthroidLevothyroxine Sodium | 252 | $20,326 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $19,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,203 | $417,616354 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $43,847 | $411,914298 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $149 | $280,036309 claims |
| AstraZenecaFarxiga | $13,692 | $84,74989 claims |
| MerckJanuvia, Janumet Xr | $5,211 | $53,94745 claims |
| AbbVieSynthroid | $312 | $20,326252 claims |
| Antares Pharma, Inc.Xyosted | $151 | $10,20211 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $177 | $4,503320 claims |
| IBSA Pharma Inc.Tirosint | $58 | $2,00315 claims |
| PfizerLevoxyl | $24 | $1,51930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Mechanicsville
- Elizabeth BondChristiansburg$7K
- Sarasi JayaratneAlexandria$0
- Peter RossFairfax$0
- Deepak KashyapFalls Church$0
- Heather FerrisCharlottesville$0
- Kate KinnairdFalls Church$0
- Jeffrey TaylorHarrisonburg$0
- Mandip RawlaNorfolk$0
- Christopher McCartneyCharlottesville$0
- Lida TabatabaeianWarrenton$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.